Health Care · Pharmaceutical Preparations · NYSE · CIK 885590 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $6.03Day +28.85%Mkt cap $2.3BP/E (FY) 14.4×1Y −5.6%Off 52W high −30.6%Vol (1Y) 58.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,545 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$17.44 |
| Implied upside+189.3% |
| Valuation confidenceLOW |
| Price impliesUNDEMANDING · 1.6% growth |
| Short interest2.0% of sh out |
| Days to cover3.7d |
| 13F net flow (QoQ)+1.51% |
| Top-10 13F concentration71.0% |
| Next report (est.)2026-10-28 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)14.4× |
| Sales (TTM)$10.85B |
| YTD−13.2% |
| 1Y−5.6% |
| 3Y−37.9% |
| 5Y−79.4% |
| Since incept. (ann.)−17.0% |
Total return through 2026-07-30 · series begins 2020-06-02. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)58.0% |
| Ann. volatility (3Y)52.5% |
| Sharpe (1Y)0.06 |
| Sharpe (3Y)−0.05 |
| Max drawdown (1Y)−46.9% |
| Max drawdown (3Y)−59.3% |
| Beta (3Y vs SPY)1.07 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| PAULSON & CO. INC. | 73.3M | $396M | 19.77% | +0.0% |
| GOLDENTREE ASSET MANAGEMENT LP | 34.7M | $187M | 9.35% | +0.0% |
| ROYAL BANK OF CANADA | 11.4M | $61M | 3.07% | +24.9% |
| NOMURA HOLDINGS INC | 9.0M | $49M | 2.43% | +3.3% |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 8.0M | $43M | 2.16% | −5.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | $40M | 2.00% | new |
| MFN Partners Management, LP | 6.0M | $32M | 1.62% | +0.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 4.2M | $31M | 1.14% | +145.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | −$3.82 | — | $2.52B | +11.7% |
| 2025-12-31 | 2026-02-18 | — | — | $2.80B | +9.3% |
| 2025-09-30 | 2025-10-29 | $0.48 | — | $2.68B | +6.8% |
| 2025-06-30 | 2025-07-30 | $0.40 | +1233.3% | $2.53B | +5.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-28 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
United Statesand Puerto Rico 60% · Other Countries 11% · CN 5% · CA 4% · PL 4%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Earnings (TTM)-$1.10B |
| Net margin1.5% |
| ROIC3.0% |
| Total debt / EBITDA6.89× |
| Sales growth 3Y8.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
